|
|
|
|
|
|
|
|
|
|
|
25.02.26 - 22:21
|
Thermo Fisher Scientific Increases Quarterly Dividend (Business Wire)
|
|
|
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0.47 per common share, payable on April 15, 2026, to shareholders of record as of March 13, 2026. This reflects a 10% increase over the previous dividend payment of $0.43.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through o...
|
|
|
|
|
|
|
|
|
|
|
|
|
10.02.26 - 03:42
|
Thermo Fisher Scientific Prices Offering of USD-Denominated Senior Notes (Business Wire)
|
|
|
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”) announced today that it has priced an offering of $3.8 billion aggregate principal amount (the “Offering”) of the following notes:
$1.0 billion aggregate principal amount of its 4.215% senior notes due 2031 (the “2031 notes”) at the issue price of 100.000% of their principal amount;
$750 million aggregate principal amount of its 4.550% senior notes due 2033 (the “2033 notes”) at the issue price of 99.783% of their principal amount;
$1.3 billion aggregate principal amount of its 4.902% senior notes due 2036 (the “2036 notes”) at the issue price of 100.000% of their principal amount; and
$750 million aggregate principal amount of its 5.546% senior notes due 2046 (the “2046 notes” and, together with the 2031 notes, the 2033 notes and the 2036 notes, the “notes”) at the issue price of 100.000% of their principal amount.
The Offering is expected to close on or about February 12, 2026, subjec...
|
|
|
|
|
|
|
|
|
02.02.26 - 15:24
|
Navinci welcomes Kjell Ruth as Chief Commercial Officer (Cision)
|
|
|
Uppsala, Sweden – February 2, 2026 – Navinci today announced the appointment of Kjell Ruth as Chief Commercial Officer (CCO). In this role, Kjell will lead Navinci's global commercial strategy and execution, supporting the company's continued expansion worldwide.
Kjell brings broad, cross-functional experience from the biotech and life science industry, spanning business development, sales, marketing, and commercial strategy. He has worked across both high-growth biotech companies and larger global organizations, most recently in Global Marketing at Thermo Fisher Scientific. His experience...
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
